🟢 Nasus Pharma is trading 11% up in pre-market after first NS003 patient enrolled and dosed

Nasus Pharma is trading at $3.95, up 10.64% in pre-market after the first patient was enrolled and dosed in its Phase 1 NS003 study.

• Announced September 29, NS003 is an intranasal ondansetron formulation; the trial evaluates pharmacokinetics and safety.
• Top-line data are expected by year-end 2026. No separate September 30 company announcement was identified; the price and percentage are from the supplied price context.